Researchers examined outcomes in peripheral blood haplo-HCT and their relation to pre-operation measurable residual disease.
2022 Tandem Meetings
Advertisement
The phase II study had enrolled 63 patients at the time of the interim analysis.
Venkata S. Thammineni, MD, and colleagues conducted a meta-analysis to assess the effect of graft CD on allo-PBSCT outcomes.
Researchers examined the relationship between extracellular vesicle antigen expression and their microRNA cargo.
The poster advanced a total of 27 "candidate protein biomarkers which may predict occurrence of aGVHD."
A studyobserved “encouragingly” positive results in reducing severe acute graft-versus-host disease (aGVHD).
The data were presented by the study’s lead author, Meredith Jo McAdams, MD, at the TCT 2022 Tandem Meetings.
Researchers presented updated data from the phase Ib/II EQUATE trial.
Researchers sought to characterize outcomes of pediatric patients who developed SR-aGVHD after allogeneic HSCT.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.